London-headquartered medical devices company and FTSE 100 constituent Smith & Nephew (LSE: SN) today announced through its Advanced Wound Management division that its new ACTICOAT Flex 3 and ACTICOAT Flex 7 products had been launched in Europe to expand the existing portfolio of ANTICOAT antimicrobial barrier dressings, used for the treatment of soft tissue injuries with high risk of infection.
Before making entry to the European market, the two new ACTICOAT Flex products were cleared for use by Health Canada in late 2008 and launched in the United States late last month.
The company said ACTICOAT Flex products were designed to treat wounds in areas of the body requiring a high level of conformability and to minimize trauma when removing the dressing.
Smith & Nephew started the day just below the opening level on the London Stock Exchange on Wednesday.